伊畅佳

Hangzhou Grand Biopharmaceutical, a core subsidiary of China Grand Pharmaceutical and Healthcare Holdings, is a specialized Chinese biopharmaceutical company focused on the development and commercialization of microbial-based medicines. The company is best known for its flagship product, Yichangjia (Bifidobacterium Tetravaccine), which is a leading live biotherapeutic in the Chinese market for treating intestinal flora imbalance and associated gastrointestinal disorders. Operating from its GMP-certified facilities in Hangzhou, the company integrates research, production, and sales to address needs in gastroenterology and metabolic health. Hangzhou Grand Biopharmaceutical's expertise lies in the stabilization and large-scale production of live bacterial strains, positioning it as a key player in the probiotic drug industry. The company's product portfolio is widely used in clinical settings across China to treat conditions such as diarrhea, constipation, and enteritis.